{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:07:14Z","timestamp":1773976034704,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1517\/13543784.2013.840289","type":"journal-article","created":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T08:37:57Z","timestamp":1380184677000},"page":"97-106","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Investigational drugs for onychomycosis"],"prefix":"10.1517","volume":"23","author":[{"given":"Aditya K","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto","place":["Canada"]},{"name":"Mediprobe Research, Inc.","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona C","family":"Simpson","sequence":"additional","affiliation":[{"name":"Mediprobe Research, Inc.","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,9,26]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1972.01620050069017"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.02.038"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.12.006"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592120-000000000-00000"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb06087.x"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2010.07.008"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02464.x"},{"key":"e_1_3_2_10_1","first-page":"379","article-title":"The prevalence and management of onychomycosis in diabetic patients","volume":"10","author":"Gupta AK","year":"2000","unstructured":"Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10:379-84","journal-title":"Eur J Dermatol"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00124.x"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00012.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00568.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.4274\/turkderm.00908"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.062"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.149.s65.5.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.453"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802497218"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00158-11"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70112-1"},{"key":"e_1_3_2_22_1","unstructured":"LAMISIL (terbinafine hydrochloride) Tablets 250 mg. Drugs@FDA: FDA Approved Drug Products 2012. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020539s021lbl.pdf [Last accessed 15 March 2013]"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04584.x"},{"key":"e_1_3_2_24_1","unstructured":"SPORANOX\u00ae (itraconazole) Capsules. Drugs@FDA: FDA Approved Drug Products 2012. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020083s048s049s050lbl.pdf [Last accessed 15 March 2013]"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.703308"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03545.x"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247588"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki105"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.12.021"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M237"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S39600"},{"key":"e_1_3_2_32_1","unstructured":"A Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects with Distal Subungual Onychomycosis. Glaxo-Smith Kline 2012. Available from: http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=114554&studyId=4ED3A7C8-ABAF-4DC7-B1A4-362C64C27D09&compound=albaconazole&type=Compound&letterrange=A-F [Last accessed 1 April 2013]"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.11.5209-5211.2003"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2116-2118.2005"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.93651"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10660.x"},{"key":"e_1_3_2_37_1","unstructured":"A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) - Full Text View - ClinicalTrials.gov. ClinicalTrials.gov 2007. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00491764 [Last accessed 30 May 2012]"},{"key":"e_1_3_2_38_1","unstructured":"NOXAFIL\u00ae (Posaconazole) ORAL SUSPENSION 40 mg\/ml. Drugs@FDA: FDA Approved Drug Products 2012. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022003s011s012 022027s002s003lbl.pdf [Last accessed 9 April 2013]"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.388-391.2004"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3272-3278.2004"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01212.x"},{"key":"e_1_3_2_42_1","unstructured":"ERTACZO (SERTACONAZOLE NITRATE) CREAM 2%. Drugs@FDA: FDA Approved Drug Products 2003. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/21385_Ertaczo_lbl.pdf [Last accessed 11 April 2013]"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969030-00009"},{"key":"e_1_3_2_44_1","unstructured":"VFEND\u00ae (voriconazole) Tablets Oral Suspension and I.V. Drugs@FDA: FDA Approved Drug Products 2011. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021266s035 021267s040 021630s026lbl.pdf [Last accessed 11 April 13]"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.04.004"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02056-12"},{"key":"e_1_3_2_48_1","first-page":"20","article-title":"Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential","volume":"6","author":"Del Rosso JQ","year":"2013","unstructured":"Del Rosso JQ, Reece B, Smith K, et al. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthet Dermatol. 2013;6:20-4","journal-title":"J Clin Aesthet Dermatol."},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02370-12"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-004-0327-1"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693780903373811"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00218-09"},{"key":"e_1_3_2_53_1","unstructured":"Flack M Robinson P Ijzerman M et al. Efficacy of Topical Nanoemulsion (NB-002) for the Treatment of Distal Subungual Onychomycosis: a Randomized Double-Blind Vehicle-Controlled Trial. NanoBio Inc 2010. Available from: http:\/\/www.nanobio.com\/News\/documents\/2010_AAD_P2108.pdf [Last accessed 11 April 13]"},{"key":"e_1_3_2_54_1","unstructured":"Ciotti S Eisma R Ma L et al. Lateral diffusion of terbinafine hydrocholride in a novel nanoemulsion. 2009. Available from: http:\/\/www.nanobio.com\/Dermatology\/documents\/148098_465_11x17.pdf [Cited 7 November 2012]"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00083-11"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.711315"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10766.x"},{"key":"e_1_3_2_58_1","article-title":"Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs","author":"Elewski BE","year":"2011","unstructured":"Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 2011; published online 20 December 2011; doi:10.1001\/archneur.63.3.noc50312","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_2_59_1","unstructured":"Zane L Pollak R. Safety and Efficacy of Tavaborole (Formerly AN2690) a Novel Boron-based Molecule in Phase 2 Trials for the Topical Treatment of Toenail Onychomycosis. Anacor Pharmaceuticals 2012. Available from: http:\/\/www.anacor.com\/pdf\/APMA%20Tavaborole%20Phase%202%20Poster.pdf [Last accessed 11 April 2013]"},{"key":"e_1_3_2_60_1","unstructured":"Mao W Seiradake E Crepin T et al. AN2718 has Broad Spectrum Antifungal Activity Necessary for the Topical Treatment of Skin and Nail Fungal Infections. Anacor Pharmaceuticals 2009. Available from: http:\/\/www.anacor.com\/pdf\/p2422.pdf [Last accessed 11 April 2013]"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05477.x"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2003)077<0556:PIOTDT>2.0.CO;2"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1562\/2004-04-22-RA-146.1"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl490"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701836977"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2008.00468.x"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693780802524522"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-10-39"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-1-r7"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/517529"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00259-12"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2013.840289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:14:26Z","timestamp":1770376466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2013.840289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1517\/13543784.2013.840289"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2013.840289","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2013-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}